Although a clinical trials agreement between representatives of the managed care industry and NIH establishes a framework for expanding patient access to experimental therapies, it is far too early to expect insurers to apply the model to clinical trials conducted by the private sector.

Last week, the American Association of Health Plans agreed to guidelines designed to encourage